^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Renal Cell Carcinoma
    Drug:Avzivi (bevacizumab-tnjn) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    12/06/2023
    Excerpt:
    Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of:…Metastatic renal cell carcinoma in combination with interferon alfa.
    Secondary therapy:
    alpha-interferon